uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients

BACKGROUND: Emerging evidence has highlighted the importance of extracellular vesicle (EV)-based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic melanoma. Considering the tumor-promoting implications of urokinase-type plasminogen activator receptor (uPAR) signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Porcelli, Letizia, Guida, Michele, De Summa, Simona, Di Fonte, Roberta, De Risi, Ivana, Garofoli, Marianna, Caputo, Mariapia, Negri, Antonio, Strippoli, Sabino, Serratì, Simona, Azzariti, Amalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112420/
https://www.ncbi.nlm.nih.gov/pubmed/33972390
http://dx.doi.org/10.1136/jitc-2021-002372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112420/
https://www.ncbi.nlm.nih.gov/pubmed/33972390
http://dx.doi.org/10.1136/jitc-2021-002372

Ejemplares similares